Report

Global Parkinson's disease (PD) treatment market is projected to witness a CAGR of 7.40% during the forecast period 2024-2031, growing from USD 4.98 billion in 2023 to USD 8.82 billion in 2031. The market is anticipated to thrive at a renowned pace during the forecast period owing to several driving forces like regulatory approvals, and growing traction from market players in Parkinson's disease.
The market of Parkinson's disease is constantly changing advances in the field of drug development, rising healthcare costs, and a growing understanding of the disease itself all shape the market. Parkinson's is a progressive degenerative neurological disorder that mostly affects movement, characterized by symptoms like tremors, rigidity, and bradykinesia. Recent innovation in therapeutic options has truly fueled the market. New drugs targeting specific pathways in the disease process have emerged, bringing out effective treatment regimens. In addition, augmenting healthcare spending, especially in developing countries, opens better access to these treatments. Also, governments are investing in research initiatives to discover novel therapies, and this will spur further growth in the market. The advanced diagnostic tools allow for diseases to be detected in the early stages, meaning that treatment might start early and, thus, lead to better outcomes for patients. There remain some barriers within the market, including the costliness of treatment and ignorance about the disease, especially in low and middle-income countries. Lack of provision of disease-modifying therapies and various adverse effects related to the available treatments can be a significant constraint in patient compliance and, by extension, overall market growth. Regular innovations and product launches maintain the market activeness and ensure the growth of the market, for instance, in May 2024, BIAL Holding, S.A. announced the launch of KYNMOBI (apomorphine hydrochloride), the first sublingual film approved in Germany for the treatment of OFF episodes in adult Parkinson's disease patients not sufficiently controlled by oral medication. The new formulation provides an effective on-demand therapy for OFF periods and motor fluctuations.
Rising Prevalence of Parkinson's Diseases
Parkinson's disease is the second most common neurodegenerative disorder globally, mostly occurring in the elderly population. The prevalence of Parkinson's is on the rise which led to heightened demand for treatment products. The dramatic rise in Parkinson's prevalence is straining healthcare systems and increasing the demand for medications, therapies, and surgical treatments. The combined direct and indirect costs of Parkinson's in the U.S. are estimated at nearly USD 52 billion per year. According to an article published in Frontiers in Neurology in May 2024, the global prevalence of Parkinson's disease was 6.1 million in 2016, and 8.5 million in 2019, and the prevalence is projected to go over 17 million in 2040. As the Parkinson's pandemic continues to grow, the need for expanded access to treatments, improved therapies, and ultimately a cure will only intensify in the coming years. While there is no cure for Parkinson's disease, another factor contributing to the high revenue generation for this market is the continuous need for medication for the patients.
Growing Investment in PD to Increase Market Growth
Neurodegenerative disease has been an active field of research including Parkinson's disease. The growing traction from market players and research promotors in this field is expected to contribute for the expansion of the Parkinson's disease treatment market. The research efforts from various organizations like The Michael J. Fox Foundation for Parkinson's Research, The Parkinson's Foundation, and others are significantly impacting the market scenario. For instance, in November 2023, PhotoPharmics, a leader in Parkinson's disease research and treatment, announced the successful first close of a USD 16 million investment round. The investment round marks a significant milestone in PhotoPharmics' mission to revolutionize Parkinson's disease treatment. The primary purpose of this investment round is to fund a pivotal clinical trial aimed at obtaining FDA market authorization for Celeste, PhotoPharmics' FDA breakthrough therapeutic device for Parkinson's disease. In another such example, Parkinson's UK invested USD 1.38 million in Mission Therapeutics Ltd's clinical trial through their Virtual Biotech program to help test a potential treatment called MTX325 in people with Parkinson's.
Carbidopa-Levodopa Segment to Dominate the Parkinson's Disease Treatment Market
Carbidopa-levodopa is the most used medication for Parkinson's disease due to its effectiveness in addressing the motor symptoms associated with the condition, thus, contributing a major share in the Parkinson's disease treatment market. Carbidopa-levodopa is used in combination for its dopaminergic effect, several notable formulations are available in the market with this combination and frequent drug launches related to the combination are anticipated to expand the market share in the forecast period. For instance, In January 2024, AbbVie, Inc. launched PRODUODOPA in the European Union for treating advanced Parkinson's disease with severe motor fluctuations and hyperkinesia or dyskinesia. PRODUODOPA is a first-and-only subcutaneous 24-hour infusion of levodopa-based therapy, providing continuous relief and extending the period of well-controlled symptoms.
North America Dominates Parkinson's Disease Treatment Market Share
North America is anticipated to be the dominating region in the Parkinson's disease treatment market during the assessment period owing to robust healthcare infrastructure that results in a high rate of diagnoses and subsequent treatment population. The concentration of leading market players like AbbVie in the region conjugated with enhanced emphasis on the prevalence of Parkinson's disease is quite high in North American countries such as the United States and the prevalence is anticipated to rise further in the future leading to further market expansion. According to the data of the Parkinson's Foundation, around one million people in the United States are living with Parkinson's disease and the number is expected to grow up to 1.2 million by 2030 making Parkinson's disease the second-most common neurodegenerative disease after Alzheimer's disease. The diagnosis rate of Parkinson's in the United States is nearly 90,000 people each year.
Future Market Scenario (2024-2031F)
The future of the Parkinson's disease market is held with the robust pipeline of products under clinical investigation which may come in the market in upcoming years. Market players like AbbVie, and Roche have promising drug candidates in the pipeline. Apart from the medications, various alternative therapies are being developed and investigated to relieve Parkinson's patients. These therapies focus on the restoration of mobility and normal body functions. One such example is neuroprosthesis, a promising corrective therapy designed and tested in November 2023, by neuroscientists from L'Institut national de la sante et de la recherche medicale (Inserm), Centre national de la recherche scientifique (CNRS) and Universite de Bordeaux in France, along with Swiss researchers and neurosurgeons, to improve the gait disorders associated with Parkinson's disease.

Key Players Landscape and Outlook
Several renowned players like AbbVie, Amneal Pharmaceuticals, and others are catering to the market for Parkinson's disease treatment. The market activity is highly evident through various mergers, acquisition and product launch deals going on among the market players. In recent times several notable deals like AbbVie's acquisition strategy and Amneal's collaboration to expand geographical presence has significantly expanded the market.
In December 2023, AbbVie Inc. and Cerevel Therapeutics Holdings, Inc. announced an agreement in which AbbVie will acquire Cerevel Therapeutics and its strong neuroscience pipeline. This pipeline includes multiple clinical-stage and preclinical candidates that have the potential to treat various diseases such as schizophrenia, Parkinson's disease, and mood disorders. The acquisition complements AbbVie's neuroscience portfolio and adds a wide range of potentially best-in-class assets that could improve standards of care for patients with psychiatric and neurological disorders where significant unmet needs exist.
In February 2024, Amneal Pharmaceuticals, Inc. announced an exclusive licensing agreement with Zambon Biotech SA, a part of the Zambon group, for the distribution of a novel oral formulation of carbidopa/levodopa extended-release capsules, known as IPX203, in the European Union, United Kingdom, and Switzerland. This medication is intended for the treatment of Parkinson's disease and is currently under review by the U.S. Food and Drug Administration. Zambon will be responsible for seeking regulatory approval and commercializing IPX203 in Europe.